GlaxoSmithKline PLC (LON:GSK) has vowed to produce 1bn doses of its pandemic vaccine adjuvant system to support the development of coronavirus (COVID19) treatment candidates.
Adjuvants are agents that improve the immune response of a vaccine and create a stronger immunity against infections.
READ: GlaxoSmithKline posts positive interim study on HIV prevention drug
The pharma giant, which will manufacture the doses next year, has confirmed several collaborations globally to identify COVID-19 candidates suitable to use the agent and is in discussion with more potential partners.
The profits generated from these deals will be reinvested in coronavirus-related research and long-term pandemic preparedness, either through GSK’s internal projects or with external partners.
Shares rose 1% to 1,671.08p on Thursday morning.